Connect your AI

Trevi Therapeutics, Inc. TRVI Other

Other at other companies

Devon EnergyDVN

0%—

American International GroupAIG

0.5%+0.2pp

Oruka Therapeutics, Inc.ORKA

-0.1%0.0pp

General MotorsGM

-$4.5M—

American International GroupAIG

$5M+53.8%

ADMA BiologicsADMA

1.5%—

Other financials

Income statement

Operating income-$14.9M-30.0%

Net income-$13.2M-27.6%

EPS (diluted)-$0.090.0%

Balance sheet

Cash & equivalents$19.4M+0.2%

Total debt$682.0K-28.7%

Total equity$172.1M+73.1%

Total assets$179.6M+67.8%

Cash flow

Operating cash flow-$16.7M-23.8%

CapEx$102.0K—

Free cash flow-$16.8M—

Valuation

Market cap$2.49B+152%

Returns & leverage

Return on equity-33.6%-9.4pp

Debt / equity0×0.0×

Current ratio24.8×+9.4×

Where this comes from

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther.

The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Trevi Therapeutics, Inc.'s other.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Trevi Therapeutics, Inc.'s other?: Trevi Therapeutics, Inc. (TRVI) reported other of $0 in Q4 2025.